Akari Q2 net loss $4.8M; raises $8.6M; AKTX-101 on track for mid-2027 Phase 1

Akari Therapeutics Plc

2026-Q2 EPS reported $0.00

Q2 2026 net loss $4.8M vs $1.9M YoY; R&D $2.1M up from $0.7M on IND-enabling work.
Cash $7.7M at June 30, 2026 vs $5.2M at Dec 31, 2025; raised $8.6M gross in quarter.
AKTX-101 progressing toward Phase 1 initiation planned for mid-2027; ASCO data on PH1 + KRAS inhibitor.
Research collaboration with Whitehawk Therapeutics on dual-payload ADCs combining PH1 with topoisomerase I payload.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.